Literature DB >> 2707983

Use of a modified symptom distress scale in assessment of the cancer patient.

S Holmes1.   

Abstract

Symptom distress was assessed in a heterogeneous sample of cancer patients using a modified version of the McCorkle and Young (Cancer Nurs. 1, 373-378, 1978) Symptom Distress scale based on a linear analogue self-assessment (LASA) scale. Validity was assessed. Reliability, based on estimation of internal consistency (Cronbach's coefficient alpha), was high (alpha = 0.97) showing the tool to be reliable and effective in assessment of symptom distress. Of the 120 patients included 73% indicated significant distress from at least one symptom, 55% from two or more and 28% from at least five. Only 25% were suffering widespread or advanced disease suggesting that the incidence of symptom distress is not, of necessity, dependent on the extent of disease. The results obtained using the modified index were compared with those previously obtained by McCorkle and Young (1978) and showed marked similarities between the different cancer patient populations. This indicates that the modified scale is no less effective in assessing symptom distress but this has considerable advantages due to its simplicity and ease of administration.

Entities:  

Mesh:

Year:  1989        PMID: 2707983     DOI: 10.1016/0020-7489(89)90047-3

Source DB:  PubMed          Journal:  Int J Nurs Stud        ISSN: 0020-7489            Impact factor:   5.837


  11 in total

Review 1.  Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

Review 2.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.

Authors:  Peter Reber; Rudolf Brenneisen; Beatrice Flogerzi; Catarina Batista; Peter Netzer; Ulrich Scheurer
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

Review 4.  The psychometric properties of cancer multisymptom assessment instruments: a clinical review.

Authors:  Aynur Aktas; Declan Walsh; Jordanka Kirkova
Journal:  Support Care Cancer       Date:  2015-04-19       Impact factor: 3.603

5.  Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study.

Authors:  Timothy J Brown; Neil Keshvani; Arjun Gupta; Hui Yang; Deepak Agrawal; Tri C Le; David E Gerber; Carlos A Alvarez
Journal:  Support Care Cancer       Date:  2020-03-02       Impact factor: 3.603

6.  Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.

Authors:  Christina M Marciniak; Santiago Toledo; Jungwha Lee; Michael Jesselson; Jillian Bateman; Benjamin Grover; Joy Tierny
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 7.  Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.

Authors:  Amy P Abernethy; Jane L Wheeler; S Yousuf Zafar
Journal:  Curr Opin Support Palliat Care       Date:  2010-03       Impact factor: 2.302

8.  Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.

Authors:  S Bader; K Jaroslawski; H E Blum; G Becker
Journal:  Clin Med Insights Oncol       Date:  2011-07-14

9.  The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours.

Authors:  Margherita J Barresi; Bruce Shadbolt; Don Byrne; Robin Stuart-Harris
Journal:  BMC Cancer       Date:  2003-12-17       Impact factor: 4.430

Review 10.  Opioid-induced constipation: pathophysiology, clinical consequences, and management.

Authors:  Lalit Kumar; Chris Barker; Anton Emmanuel
Journal:  Gastroenterol Res Pract       Date:  2014-05-05       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.